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ABSTRACT
NOVEL ADAPTOR-DEPENDENT DOMAINS PROMOTE PROCESSIVE
DEGRADATION BY CLPXP
SEPTEMBER 2011
KEITH ROOD, UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Peter Chien
Protein degradation by ATP dependent proteases is a universally conserved
process. Recognition of substrates by such proteases commonly occurs via direct
interaction or with the aid of a regulatory adaptor protein. An example of this regulation
is found in Caulobacter crescentus, where key regulatory proteins are proteolysed in a
cell-cycle dependent fashion. Substrates include essential transcription factors, structural
proteins, and second messenger metabolism components. In this study, we explore
sequence and structural requirements for regulated adaptor mediated degradation of
PdeA, an important regulator of cyclic-di-GMP levels.
Robust degradation of PdeA is dependent on the response regulator CpdRin vivo
and in vitro. Here, I structurally identify a novel PAS domain in PdeA that is necessary
and sufficient for CpdR mediated PdeA degradation. The PAS domain was found to
contain a unique dimerization element that is associated with PdeA function.I show
specifically that PdeA engages ClpXP through C-terminal recognition motifs. Finally,
we present evidence that PdeA contains cryptic ClpXP recognition sites that are revealed
during partial processing. Due to these uncommon degradation characteristics of PdeA,
unique proteolytic insights may be gained by investigating this model system.
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CHAPTER 1
INTRODUCTION

The ClpXP protease plays a role in processing and degrading proteins necessary
for bacterial cell-cycle progression(5). Degradation of these substrates occurs either via
direct interaction with ClpXP or through mediation by an adaptor protein(7,11). In
addition, many of these substrates contain terminal recognition sequences specific for
recognition by ClpXP(3,11,12).Among these substrates is a regulator of cyclic-di-GMP
levels in the cellknown as PdeA(6).Cyclic-di-GMP is a small molecule known to regulate
expression of genes relevant to biofilm formation, flagellar activity and translational
initiation(1,8,9).Furthermore, PdeA is degraded in a cell-cycle dependent fashion, leading
me to believe it carries a necessary role in proper cell function(6).In this thesis, I
investigated the structural and degradation characteristics of PdeA. To do this, I
conducted my studies in the freshwater bacterium Caulobacter crescentus.
C. crescentus is most notably defined by its obligate morphological transition
during cell division. At any given time, the bacterium can be found in one of two cell
types, swarmer or stalk. Swarmers have an anterior flagellum that allows them to swim
and search for nutrients. Stalks are stationary and serve largely to divide and produce
more swarmer cells(10). As a result, there are many proteins that are produced and
degraded during cell division to accommodate either one of these cell types. One of these
proteins, PdeA, is degraded in a regulated fashion during cell division and represents a
model protein for studying the general properties of degradation that go on in such
division.
1

PdeA has three key domains, two of which are commonly associated with cyclicdi-GMP regulation. From N to C-terminus, PdeA has a previously uncharacterized PAS
domain followed by a degenerate GGDEF domain connected via a short linker to an EAL
domain (described below and see Figure 1). The PAS domain is responsible for
degradation and for an as yet unknown function in PdeA. The degenerate GGDEF and
EAL domains are associated with regulation of cyclic-di-GMP in PdeA(6).
A large portion of this thesiscenters on identifyingthe PAS domain and
characterizing it structurally. The first indicationI had that PdeA contained an N-terminal
PAS domain was a simple BLAST search on the first 130 amino acids of PdeA.
Although the search identified this N-terminal sequence of a PAS domain, I was skeptical
of the result as PAS domains have little sequence homology.Amino acid sequence
alignments yield E-values between 1 and 3 and contain 30% or less sequence homology.
However, PAS domains are structurally homologous(13). We therefore crystallized the
first 130 amino acids of PdeA and were able to identify it as a PAS domain. Later in this
paper, more detail will be given on the exact characteristics of this domain.
GGDEF and EAL domains have opposite function in terms of cyclic-di-GMP
regulation. GGDEF domains generally cyclize two molecules of GTP into one of cyclicdi-GMP(8,9). Alternatively, EAL domains are phosphodiesterase domains that linearize
cyclic-di-GMP into pGpG(8,9). Despite containing both of these domains, PdeA appears
to only actas a phosphodiesterase. likely due to mutations in the degenerate GGDEF
domain that disable its ability to cyclize GTP. However, the GEDEF domain can still
bind GTP to allosterically regulate the activity in the EAL domain(6).
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Figure 1: Cyclic-di-GMP
GMP Regulation and PdeA Primary Structure: (top) Cartoon of cycliccyclic
di-GMP
GMP cyclization and linearization. Cyclic
Cyclic-di-GMP
GMP is commonly cyclized by GGDEF
domains associated with Diguanylate Cyclases and linearized by EAL domains associated with
Phosphodiesterases. Cyclic
Cyclic-di-GMP regulates sessility/biofilm
film formation, cell cycle progression
and motility. (bottom) Primary structure of PdeA: left most domain is at N
N-terminus,
terminus, right most
domain is at C-terminus.
terminus. The degenerate GEDEF domain only serves to regulate the EAL
domain, which linearizes cyclic
cyclic-di-GMP.

PdeA levels are regulated through degradation by the ClpXP protease complex.
ClpXP is a complex comprised of the hexameric AAA+ unfoldase, ClpX, and the
tetradecameric protease ClpP(5). The AAA domains of ClpX can bind up to four ATP
molecules at a given time, but only hydrolyze a single ATP at a rate of approximately
100 molecules of ATP/minute(14). Hydrolysis results in conformational changes of the
unfoldase domains to allow pulling of a substrate through the inner pore of the complex.
ClpP is a serine protease with an active catalytic triad that cleaves polypeptides passed to
it via ClpX(5).
Substrates that interact directly with ClpX normally contain terminal recognition
tags, which allow for binding and processing(5).In the case of PdeA, a single
ingle domain
response regulator, CpdR(4), is required for highly processive degradation. PdeA
contains no obvious terminal or internal recognition tags. The exact mechanism of CpdR
3

mediation is currently unknown. However, here, I present a model thatsug
suggests CpdR
could mediate ClpX recognition of PdeA by delivering PdeA to the ClpX pore(Figure
pore
2).

Figure 2: Model of CpdR--Mediated PdeA Degradation by ClpXP: A dimer of PdeA is bound
by an adapter CpdR, which then delivers PdeA to the ClpX pore for recogn
recognition.
ition. ClpX then
hydrolyzes ATP, unfolding PdeA and directing it into ClpP for degradation

In this thesis, I present the struc
structural requirements of PdeA for interaction with
CpdR. Additionally, Iclarify
clarifythe characteristics of PdeA degradation outside
side and inside
the cell andquantify the effects that result from truncating or mutating the PdeA structure.
Tests outside the cell give us a picture of what happens in an isolated degradation system.
Tests inside the cell give us a picture of how PdeA ddegradation
egradation occurs in the living
livi
system, as well as insight into the issue of what structural components are required for
normal PdeA function.
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CHAPTER 2
DEGRADATION DETERMINANTS OF PDEA
CpdR is a necessary adaptor fo
for PdeA degradation by ClpXP.In Fi
present a table of degradation assays for various mutants and truncations of PdeA
described below. The degradation assay is performedin vitro, and includes a simple
mixture of ClpP, ClpX, an ATP regeneration mix to allow for constant levels of A
substrate of interest and CpdR if necessary. For each protein construct, we tested the
degradation properties with CpdR present and absent.

Figure 3: Degradation and CpdR Dependence of PdeA Protein Constructs:
structure, names, and SDS-PA
PAGE degradation results of various PdeA protein constructs. Tests
were done in the presence and absence of 2.5uM CpdR. Timepoints are indicated above
degradation experiment sets. Reaction contents: 0.4uM ClpX(6), 0.8uM ClpP, 4mM ATP,
75ug/ml Creatine Kinase,
ase, 5mM Creatine Phosphate, 1mM GTP, 2.5uM Protein construct. Half
lives: WT:19min, R280:24min, E265:105min, G130:76min

Our first goal was to determine directionality of PdeA degradation. To test which
terminus of PdeA was engaged by ClpX
ClpX, I mutated the last C-terminal residues of PdeA
from arginine and glycine to two aspartic acids (DD). It is known that ClpX has
difficulty recognizingpolar residues as a C-terminal motif(18,19).Therefore, when we
5

made these mutations, no degradation of the substrate occurred. We attribute this lack of
degradation to a lack of recognition by ClpX when the cc-terminal
terminal DD residues come in
close proximity of the ClpX pore (Figure 4).. Since there is no degradation whatsoever,
we can make the argument that the C
C-terminus
terminus is the initial recognition site of PdeA by
ClpX.

Figure 4: Theoretical Model of PdeA
PdeA-DD Interaction with ClpXP: PdeA-DD
DD contains a cc
terminal DD mutation which causes ClpX to be unable to recognize PdeA properly, ultimately
leading to no degradation
ation of the protein.

This result was particularly interesting because I had made truncations of PdeA
prior to the PdeA-DD
DD mutation that could be degraded regardless of the C-terminal
C
amino acids. I made truncations R280, E265 and G130 (Figure 3).. R280 is a version of
PdeA thathas
has arginine 280 as its cc-terminal
terminal amino acid and contains no EAL domain.
E265 is a version of PdeA withglutamic acid 265 as its C-terminal
terminal amino acid and lacks
the EAL domain, as well as the linker connecting the GEDEF and EAL domains.
do
G130
is a version off PdeA with glycine 130 as its C
C-terminal
terminal amino acid and contains only the
first 130 amino acids.All
All of these truncations are recognized by ClpX regardless of
having c-terminal
terminal residues that do not represent any known degradation tags.
Furthermore, this result suggests PdeA is able to reengage ClpX after partial processing,
an event that cannot normally occur in substrates containing only terminal recognition
tags(7,12)as the once the recognition tag has been degraded, the protea
protease
se can no longer
bind the substrate (Figure 5).
5).This suggests that PdeA either has cryptic recognition tags
6

that are exposed during partial processing(20), or that PdeA has no internal degradation
stop sites.

Figure 5: Theoretical Model of PdeA Partial Protein Reengagement: (top) A protein substrate
with a c-terminal
terminal degradation tag (red) gets degraded partially and is unable to reengage ClpX.
(bottom) PdeA is degraded partially, but can still reengage ClpX regardless of its c-terminal
c
amino acids.

My next goal was to isolate the domain on PdeA that interacts with CpdR. For
many substrates of proteolysis, the adapter binding site is just upstream of the protease
recognition site(15,16).However, this was not the case for PdeA. All of the truncations
trun
listed above were degraded in a CpdR
CpdR-dependent
dependent fashion, suggesting that the N-terminal
N
130 amino acids were the key for CpdR interaction. I made a final truncation
thatincluded
included just the GGDEF domain (L131
(L131-E265).
E265). This construct included a SUMO
histidine
tidine tag of roughly the same size as the first 130 amino acids on the N-terminus
N
to
stand in place of the removed domain. The SUMO tag has no effect on degradation of
substrates. Controls were done with a SUMO
SUMO-tagged version of E265 thatshows
that
normal
CpdR-dependent
dependent degradation behavior
behavior(Figure 3). The SUMO-tagged
tagged L131-E265
L131
was
not degraded in the presence or absence of CpdR. Such a result strongly suggests that the
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first 130 amino acids domain arenecessary and sufficient
sufficientfor CpdR dependent PdeA
degradation (Figure 6).

Figure 6: Theoretical Model of Necessary Domain Interaction: Without the N-terminal
N
PAS
domain, CpdR can no longer interact with PdeA for delivery purposes.

Next I wanted to know if degradation of PdeA in vivo was dependent on these
same domains.II expressed WT PdeA and a version of PdeA without the first 130 amino
acids (∆PAS) using a plasmid
plasmid-based xylose-inducible systemin Caulobacter lacking
native PdeA (∆PdeA
PdeA cells)
cells). Cultures containing these plasmids were grown in inducing
conditions overnight. The next day, cultures were back diluted to the sameOD600 and
allowed to grow another 90 minutes. The culture was then divided in half and cells were
pelleted in separate tubes. One pellet was resuspended in inducing media, while the other
was resuspended in media containing glucose to turn off protein induction. Then, I
monitored degradation of the proteins over time using western blotting and obtainedthe
results in figure 7.

Figure 7: Importance of the PAS Domain in vivo: (top) Primary structure of tested
protein constructs WT PdeA amd ∆PAS. (bottom) Results of in vivo degradation assay in
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inducing and non-inducing conditions. Assay was initiated for each culture at the same
optical density.
When comparing results of induced strains of PdeA to that of the ∆PAS, I see that the
neither PdeA nor the ∆PAS protein bands disappear over time. This constant protein level
is the expected result when protein is under continuously inducing conditions.When
comparing results of non-induced strains of PdeA to that of ∆PAS, I see that PdeA is
degraded rapidly as I expect. Additionally, ∆PAS appears to not be degraded over time
as the protein band density stays constant over time. Furthermore, the overall protein
levels of ∆PAS per OD600 is higher than that of WT PdeA.These results strongly suggest
that the first 130 amino acids are necessary for PdeA degradation in vivo as well as in
vitro. Presumably, degradation cannot happen in the cell because CpdR is unable to
deliver ∆PAS to ClpXP.
To better understand the exact effect CpdR has on mediating degradation, I
sought to investigate the kinetics of a PdeA degradation experiment. There is more than
one way an adaptor for proteolysis could function.One mechanism could be to assist in
tethering a substrate to bring it in closer proximity to the protease(15). An alternative
mechanism would be to change conformation of either a substrate or the protease. A
conformational change of a substrate could result in better binding to the protease
recognition site while a conformational change in the protease could result in a higher
binding capacity for substrates(16).Adaptors could also theoretically affect either the
affinity of a substrate to bind the protease or the overall rate of degradation of a substrate
by the protease.
The mechanism of an adaptor can be indirectly investigated through use of
Michaelis-Menten kinetics. The Michaelis-Menten equation relates the initial rate of an
9

enzymatic reaction to the concentration of a substrate. In the case of CpdR mediated
degradation of PdeA, we can equate the rate of reaction to the speed at which CpdR
delivers PdeA to ClpXP. This is done by titrating substrate concentration in the
degradation assay with a constant amount of CpdR. Plotting the initial degradation rates
vs. [substrate] gives us a curve that isfit to find the two values relevant to characterizing
the effect of CpdR. One of the values is the Vmax, which is the maximum rate of
degradation by ClpXP. The other value is the KM, which is the concentration of substrate
at which the degradation rate is half of the Vmax. If addition of CpdR changes the
Vmaxin saturating substrate conditions, then CpdR would serve to change the degradation
rate, implying enhancement of inherent ClpXP protease activity. If addition of CpdR
changes the KM, then CpdR would serve to change the affinity of a substrate to bind
ClpX. If addition changes both, then a combination of these models may be present.
However, the mechanistic effect of a protease adaptor is difficult to quantify if the
substrate cannot be degraded in the absence of the adaptor. To quantitatively test the
effect of CpdR, we made an EGFP labeled version of E265 containing a c-terminal ssrA
tag. The ssrA tag(7,12,15)promotes degradation of E265 by ClpXP without requiring
CpdR.In Figure 8, we see that CpdR serves to decrease the KM of degradation three-fold,
but has little effect on the Vmax. This supports our modelthat CpdR serves largely to
increase the affinity of a substrate to bind ClpX by acting as a simple tether.

10

Figure 8: Kinetics of CpdR Binding: Michaelis-Menten
Menten curves of initial degradation rates of an
N-terminally
terminally EGFP labeled E265 with a C
C-terminal ssrA degradation tag at increasing
concentrations. CpdR concentration was saturating at 2.5uM in all reactions that it was present.
Other reaction conditions: ClpX 0.2uM, ClpP 0.4uM, ATP 4mM, 75ug/ml Creatine Kinase, 5mM
Creatine Phosphate, GTP 1mM.
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CHAPTER 3
STRUCTURAL COMPONENTS OF THE PAS DOMAIN
To find out why the PAS domain is necessary and sufficient for degradation, we
investigated the domain structurally. PAS domains contain very little sequence
homology, and are therefore difficult to characterize through alignment. However, most
PAS domains have similar structural characteristics.Some of the common structural
characteristics are a multi-stranded beta sheet core and a ligand binding site(13).In
collaboration with the Garman lab,I crystallized G130, phased with mercury compounds,
and solved the structure to 1.7 Angstrom resolution (Table 1).
Table 1: Crystallographic Statistics
Space group
Cell dimensions
a, b, c (Å)
α, β, γ (°)
Resolution (Å)
Rmerge
I /σI
Completeness (%)
Redundancy
Refinement
Resolution (Å)
No. reflections
Rwork / Rfree
No. atoms
Protein
Water
B-factors
All atoms
R.m.s deviations
Bond lengths (Å)
Bond angles (°)

C121
63.8,41.9,48.7
90, 90, 107.5
1.7(1.74-1.70) *
7.4(37.7)
32.8(2.35)
84(28)
10.3(5.8)
1.7
10920
0.19/0.22
887
119
14.3
0.007
1.1

*highest resolution shell in parentheses
The structure showeda five-stranded beta sheet core and a possible binding pocket
flanked by two alpha helices (Figure 9b and c). These propertiesindicatethat the Nterminal domain of PdeA is indeed a PAS domain. Only one copy of the protein was
12

present in the asymmetric unit
unit;; however a dimer was formed betweencrystallographically
related monomers.. At the interface between the two monomers was a 24 amino acid long
N-terminal
terminal alpha helix that appeared responsible for thisdimerization.

a.

b.

c.

d.

Figure 9: Characteristics of the PAS Domain: a.) Image of crystal packing indicated PAS
domain dimerization. b. & c.) The PAS domain can be identified as such by a 5-stranded
5
β-sheet
core (b. in red) and 2 flanking surface α-helices
helices (c. in red) that could be involved in a small ligand
binding operation. d.) A unique N
N-terminal
terminal helix (in red) which appears to be responsible for
domain dimerization.

To validate that the N
N-terminal
terminal helix was responsible for dimerization, we made
another truncation of PdeA with the first 24 amino acids removed (∆N-PdeA
PdeA). We then
compared the UV-trace
trace from a gel filtration experiment of ∆N-PdeA to that of native
PdeA. In Figure
igure 5, gel filtration traces indicate that native PdeA elutes as a dimer,
while∆N elutes as a monomer. This evidence strongl
strongly
y suggests that the N-terminal
N
helix
13

is the main structural element for PdeA dimerization. As ∆N-PdeA
PdeA is degraded similarly
towildtype
wildtype PdeA (Figure 10), dimerization cannot be critical for either substrate
recognition by ClpXP or adaptor binding.

a.

c.

b.

d.

Figure 10: N-terminal
terminal Helix is Responsible for PAS Domain Dimerization: a.) Gel filtration
trace comparison of WT PdeA and ∆N.
N. WT PdeA elutes at a volume closely representative of a
dimer, while ∆N-PdeA
PdeA elutes at a volume closer to that of a monom
monomer.Relevant
er.Relevant molecular weight
standards marked at top of graph. Apparent molecular weights calculated from column standard
curve of 6 different proteins. b. & c.) Different views of PAS domain dimers. Note the interface
between N-terminal
terminal helices on each monomer. d.) Degradation assay of PdeA vs.∆N.
vs.
Note the
similar rate of protein degradation.
degradation.Reaction
Reaction contents: 0.4uM ClpX(6), 0.8uM ClpP, 4mM ATP,
75ug/ml Creatine Kinase, 5mM Creatine Phosphate, 1mM GTP, 2.5uM CpdR, 2.5uM Protein

The question I wanted to address through this crystal structure was what part of
the PAS domain interacted with CpdR. I addressed this question through mutagenesis of
the PAS domain. I did a multiple sequence alignment of the C.crescentus
rescentus PdeA PAS

14

domain with homologous proteins in other alpha-proteobacteria.. Few residues were
conserved among the proteins except for one arginine that corresponded to R69 in the
PdeA PAS domain. After investigation of the PAS domain crystal structure, I found that
R69 was also a surface residue(Figure 11). I decided to mutate arginine 69 to alanine
(mutant called R69A).The rate of R69A degradation is much lessthan
an that of native PdeA
(Figure 11). While slow, R69A is still degraded in a CpdR-dependent
dependent fashion, indicating
ann interaction between the two still occurs but is significantly compromised.
compromised

d.

Figure 11: R69A Heterodimerization in vitro: a.) Comparison of R69A degradation rate to that
of WT PdeA. (top) Images of SDS
SDS-PAGE
PAGE visualization of R69A band in degradation assays.
(bottom) Image band density quantification of SDS
SDS-PAGE
PAGE results plotted as [Protein] vs.
Time(min). Reaction contents: 0.4uM ClpX(6), 0.8uM ClpP, 4mM ATP, 75ug/ml Creatine
Kinase, 5mM Creatine Phosphate, 1mM GTP, 2.5uM CpdR, 2.5uM Protein construct b.) Similar
comparison as in a. of R69A degradation rate to that of R69A pre
pre-incubated
incubated overnight with
equimolar amounts of G130. (top) Images of SDS
SDS-PAGE
PAGE visualization of R69A band in

15

degradation assays with and without equimolar G130. (bottom) Quantification as described
above. Reaction contents are otherwise the same as in a. c.) Model of R69A heterodimerization.
(top) A PdeA homodimer can successfully bind CpdR and be degraded. (middle) A R69A
homodimer (red) binds CpdR less well and therefore cannot be degraded in the same way as WT.
(bottom) A PdeA-R69A heterodimer allows CpdR binding and degradation of both WT and
R69A. d.)Structure of PAS domain with R69A colored red.

It was unclear whether the decrease in degradation rate could be attributed to a
deficiency in CpdR binding or a structural defect in R69A thatcaused it to be degraded
more slowly than WT PdeA. To formally rule out a structural defect, I tested whether
R69A could heterodimerize with G130 (the isolated PAS domain). The heterodimer of
R69A and G130 would therefore have one monomer which could bind CpdR (G130)
efficiently, and one monomer that could not (R69A). I compared the disappearance of
R69A in the presence and absence of G130. R69A was degraded faster (Half-lives:
–G130:~250min, +G130:~140min) in the presence of G130, indicating that R69A had
heterodimerized with G130 and was degraded more efficiently. If the degradation rate
had not increased under these conditions, I would have attributed the slower degradation
rate of R69A to an internal structural defect that caused ClpXP degradation to be
inhibited. This increase I saw in degradation rate could be attributed to the G130
monomer binding CpdRfacilitating delivery of itself and the associated R69A to ClpXP.

16

CHAPTER 4
EFFECTS OF PDEA DEGRADATION CHANGES IN THE CELL
Due to the importanceof PdeA in cell-cycle progression, division and motility, I
observed the effects of my PdeAconstructs on motility in vivo. Motility of C.crescentus
cells can be visualized by inoculation of cells in a low percent agar plate of the
appropriate media. Submerging a colony into the agar via pipet tip causes the cells to
grow in a circular pattern with a circumference of a size proportional to cell motility.
The more motility a given cell line has, the larger the circumference.
I made cell lines of WT C.crescentuscontaining a plasmid DNA with our protein
constructs of interest under a xylose inducible expression system. Additionally, I made
∆PdeA cell lines with the same set of constructs.The plasmid contained constructs PdeA,
∆N, ∆PAS, R69A and PdeA-DD. I then subjected each line to a set of high expressing
and low expressing motility tests. In these tests, when xylose is present, there is a high
amount of expression. When xylose is not present there is still a low level of expression
of the protein. The results were compared to colonies grown from WT cells expressing
wildtype PdeA added which acted a control for normal motility. Results were also
compared to a ∆PdeA cell line as a control for low motility (Figure 12).
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Figure 12: Effects of PdeA Constructs on Cellular Motility: (top) Images of colony growth for
a given protein construct in high expression or low expression conditions. (bottom) Graph
Grap of
image quantification of colony area normalized to WT area.

These sets of testsallow us to draw several important conclusions. Comparing the
high motility control to the low motility control, we can roughly equate PdeA
functionality to motility. Since there is high motility when PdeA is present and low
motility when PdeA is absent, this suggests PdeA function is a determinant of motility.
When comparing high expression of PdeA to low expression in both WT and ∆PdeA cell
lines, we see roughly the same motility. This suggests that even low levels of WT PdeA
can be functional enough to yield high motility.
Unlike WT, when comparing high expression of ∆N
N to low expression in ∆PdeA
cells, we see a difference inmotility. W
When ∆N
N is expressed in low amounts, motility
resembles that of a low motility strain. However, highexpression of ∆N
N recovers some
motility. This suggests that the ∆N
N version of PdeA is partially functional. We know
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from in vitro tests that ∆N is a monomeric form of PdeA. The results of this motility test
can additionally mean one of two things. High expression of monomeric PdeA drives
either functional recovery or dimerization resulting in an almost WT motility.
Neither high nor low expression of ∆PAS in ∆PdeA cells can recover motility.
We know from in vitro and in vivo tests that ∆PAS cannot be degraded. This result
brings to light three distinct possibilities: degradation of PdeA is required for correct
function, the PAS domain is required for PdeA function independent of degradation, or
some combination of both. To address these possibilities,IexpressedPdeA-DD(which
cannot be degraded, but contains an intact PAS domain). Expression of PdeA-DD
resultsinhigh motility underlow expressing conditions and low motility underhigh
expressing conditions. Therefore the PAS domain is not only necessaryfor proper
degradation of PdeA, but also plays a role in PdeA function.
Finally, the PdeA-DD result suggests that too much PdeA can negatively affect
motility. Since PdeA-DD cannot be degraded, its function in the cell never ceases. This
means cyclic-di-GMP is constantly being degraded by PdeA-DD, and ultimately results
in low motility as we can see in the high expression result in both WT and ∆PdeA cells.
Low expression allows for some breakdown of cyclic-di-GMP by PdeA-DD but not too
much, yielding high motility.
When testing the R69A mutant in ∆PdeA cells, I saw the same results as in the
PdeA-DD tests. This result is in agreement with our invitro studies. We know that the
R69A is degraded at a very slow rate in vitro, and that PdeA-DD is not degraded. The
motility results of R69A therefore mimic those of PdeA-DD. The same conclusion can be
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reached that R69A is functional and healthy for the cell in low levels, but too much can
yield low cell motility.
The motility results of R69A in WT cells appear to validate the in vitro
heterodimerization tests. High expression of R69A in ∆PdeA cells shows lower motility
than that of high expression of R69A in WT cells. Since WT cells contain a native
version of PdeA that has normal CpdR binding capacity, this suggests when some of the
R69A heterodimerizes with the WT PdeA both species are degraded. The degradation of
the heterodimers serves to partially recover motility even in high expression levels of
R69A.
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CHAPTER 5
CONCLUSIONS
Over the course of this study, I have studied PdeA degradation using techniques
in the fields of molecular biology, structural biology and cellular biology. Therefore,
there are many conclusions we can draw regarding PdeA degradation that paint a
captivating picture.
We now know that a PdeA dimer is degraded in a CpdR-dependent fashion from
C to N-terminus. Degradation of PdeA initiates when CpdR binds to an N-terminal PAS
domain and delivers PdeA to ClpX for recognition. A key residue in CpdR binding is
R69A, which lies at the top of a unique PAS domain structural motif.After recognition,
PdeA undergoes processive degradation which, if interrupted at any point, allows for
reengagementto ClpX regardless of the resulting c-terminal residues. Additionally, if
degradation of PdeA does not occur properly then cells suffer motility deficiencies.
Proper degradation and function of PdeA in the cell is dependent on activity of the PAS
domain and dimerization via an N-terminal helix. Therefore, these deficiencies may lie
in improper regulationof PdeA function via degradation.
With this understanding of PdeA degradation and the structure of the PAS domain
in hand we can now address new questions. Why is normal motility of the cell so directly
related to PdeA function and degradation? PAS domains normally bind some ligand Does the possible ligand binding site play a role in PdeA function? Is CpdR a ligand? Is
the PAS Domain capable of interacting with more than just CpdR? Why can PdeA so
readily reengage ClpX?
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Proteolysis of PdeA is serving as a direct regulator of integral morphological
features during cell division. It is very possible that PdeA falls within a pathway of
enzymes and metabolites that regulate key functions for motility adaptation. Such a
pathway could entertain large complexities due to the involvement of CpdR and the
functionality in the PAS domain. The PAS domain responds to signals from a regulatory
adapter and also plays a role in advancing proper cell growth. PAS domains could
therefore have an important role in communication between posttranslational regulators
and proteins associated with cell division. Furthermore, PdeA activity is regulated by its
degradation. Linking the N-terminal PAS domain that binds adaptors to a C-terminal
degradation tag means PdeA is able to reengage ClpX during partial processing. This
leads me to believe that proper destruction of PdeA may also have an unknown purpose
in the proper cell growth. Careful study of the underlying determinants of PdeA
degradation, as well as its interconnectivity with cell cycle progression could greatly
deepen our capability of understanding the purpose and mechanisms of proteolytic
regulation.
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CHAPTER 6
MATERIALS AND METHODS
6.1 Material Nomenclature
6.1.1 Buffers
1,)Lysis Buffer: 50mM Tris pH 8.0, 300 mM NaCl, 10% Glycerol, 10 mM Imidazole
2.)Elution Buffer: 50mM Tris pH 8.0, 300 mM NaCl, 10% Glycerol, 300 mM Imidazole
3.)H-buffer: 25mM HEPES pH 7.5, 100mM KCl, 10mM MgCl2, 10% (v/v) Glycerol
6.1.2 Media
1.)LB (Luria Broth): 1% (w/v) Bacto-Tryptone, 1% (w/v) NaCl, 0.5% (w/v) yeast extract
2.)PYE:0.2% (w/v) peptone, 0.1% (w/v) yeast extract, 0.5 mM CaCl2, 0.8 mM MgS04
3.)Motility plates: 0.2% (w/v) peptone, 0.1% (w/v) yeast extract, 0.5 mM CaCl2, 0.8 mM
MgS04, 0.3% (w/v) Agar, 0.2% (v/v) Xylose (present only in high expression plates)
6.1.3 Western Blotting
1.)Primary antibody: Monoclonal ANTI-FLAG® M2 antibody produced in mouse
2.)Secondary antibody: Goat Anti-Mouse IgG, HRP Conjugate polyclonal antibody
(Millipore, Cat# 12-349)
Apparatus: Hoefer TE70X Semi-dry Transfer Unit
6.2 Protein Purification
6.2.1 HisSUMO tagged Proteins
6.2.1.1 Grow-up and Initial Purification Step
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Included in the HisSUMO tagged set are PdeA, PdeA-DD, CpdR, R69A, R280,
E265, G130, L131-E265, ∆N, and ∆PAS. All HisSUMO tagged proteins are expressed
using the pET23b vector under the T7 Promoter system. Immediately downstream of the
promoter is the HisSUMO sequence which adds a 6-histidine tag attached to a small
protein adapted for solubility enhancement. Protein constructs are inserted downstream
of the HisSUMO tag and the resulting proteins are produced with an N-terminal
HisSUMO tag that can be used for Ni-NTA column affinity. The HisSUMO tag is also
cleavable by the Ulp1his enzyme. The tag can therefore be used to retain the protein on a
nickel-NTA purification column and then later be excised for experimental purposes. All
vectors were transformed into BL21 cells for high expression purposes.
2 days prior to purification, an overnight culture in appropriate volume of LB with
100ug/ml Ampicillin was started. The pET23 vector contains a cassette for Ampicillin
resistance. 10 ml of overnight cell cultures containing the vector of interest was started
for every liter grown up the following day. Cultures were incubated at 37oC.
The following day, 10 ml of overnight culture was added for every liter (1:100
dilution) of cells grown up in fresh media containing the same ingredients as the
overnight media. 4-6 liters were incubated at 37 oC shaking at 250 RPM until growth
reached an OD600 between 0.4 and 0.8.Cultures were then induced by adding 0.4 mM
IPTG and allowed to continue shaking for 3-5 hrs. Induction with IPTG turns on a T7Promoter region on the pET23 vector that initiates constitutiveexpression of the
downstreram protein. Cells were pelleted at 6,000 x g for 15 minutes. Supernatant was
discarded and pellets were resuspended in Lysis buffer (7.5ml buffer for each 0.5 L of
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pellet. The lysis buffer is used as a resuspension agent because it is effective for lysis of
the cells and purification purposes. Pellets were then frozen at-80 oC until the next day.
On the next day, a Ni-NTA column was poured, 1 ml bed for every 1 L of cells
prepped and equilibrated into lysis buffer. Equilibration into the correct buffer is
required or else the protein could aggregate on the column. Cell pellets from above were
thawed and lysed using a microfluidizer under 14,000psi of pressure. Lysate was then
pelleted at 15,000 x g for 20 minutes. Supernatantwas saved separately and pellet was
discarded. The purpose of these steps is to break apart cells to expose proteins, and also
to separate the cell debris from components in solution.
Ni resin was resuspended with a small amount of lysis buffer and added to lysate
supernate and then allowed to shake gently at 4 oC for one hour. During this time, the
proteins in solution that react with Ni will bind to the resin. It is important to take care in
not disturbing the mixture too much at this point and keep the temperature cold.
Otherwise, protein aggregation could occur.Resin was spun down in a tube at 1,000 x g
for 5 minutes and supernatent was collected as a Flow-through sample. Resin pellet was
resuspended in a small amount of lysis buffer and poured back into a column. Column
was then washed with at least 25X column volumes of Lysis buffer and wash is collected.
This wash serves to separate weakly bound proteins that are not HisSUMO tagged, from
the resin. Protein is eluted from the column by adding 2 x 1.25 columnvolumes of
elution buffer and collected. The elution buffer contains a high amount of Imidazole
which binds in place of histidine residues, allowing for the tagged protein to elute from
the column. Elutions are concentrated or diluted to 2.5ml (for buffer exchange purposes)
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and buffer exchanged (protocol 6.10) into either lysis buffer for further purification as in
protocol 6.2.1.2 or into H-buffer for various testing purposes.
6.2.1.2 HisSUMO Cleavage and Secondary Purification Step
After buffer exchange into lysis buffer, at least 75ul of >100uM Ulp1his was
added to SUMO-tagged protein and incubated at 4 oC overnight. During this time,
Ulp1his is cleaving the HisSUMO tag from the protein. The next day, cleaved protein
was applied to a 2 ml (bed volume) of Ni-NTA resin. Flowthrough was collected and
passed over column again. This final flowthrough contains untagged protein thatcan be
concentrated to 2.5ml and buffer exchanged (protocol 6.9) into H-buffer for testing
purposes.
To recover remaining cleaved HisSUMO tag or HisSUMO tagged protein the
following steps were executed. Add 2x3ml of Lysis Buffer to column and collect. Add
5ml of Elution Buffer to column and collect. This elution will contain cleaved HisSUMO
tag or HisSUMO tagged proteinthatcan be buffer exchanged into H-buffer or other buffer
for testing purposes.
6.2.2 ClpX
The purification of this protein followed steps noted in the methods section of reference
3.
6.2.3 Native ClpX
The purification of this protein followed steps noted in the methods section of reference
3.
6.2.4 ClpP
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The purification of this protein followed steps noted in the experimental procedures
section of reference 7. All aspects are the same except the ClpP expressed was expressed
using a pQE70 vector.
6.3In vitro degradation assay
Degradation assays final concentrations were as follows unless noted otherwise:
ClpX 0.4uM, ClpP 0.8uM, ATP 4mM, 75ug/ml Creatine Kinase, 5mM Creatine
Phosphate, GTP 1mM, substrate 2.5uM, CpdR 2.5uM (if present). Reaction components
are mixed and extra volume is filled with H-buffer. H-buffer provides an environment in
which the ClpXP machinery can function correctly. In the absence of CpdR, the volume
of protein is substituted with H-buffer. Reaction is begun by adding ATP, Creatine
Kinase, and Creatine Phosphate to a master mix containing ClpX, ClpP and GTP. All
reactions are carried out at 30 oC.
6.4 In vivo degradation assay
Strains were expressed in a 477Caulobacter cell line inducible with xylose and
contained either WT genes or WT genes lacking a native PdeA (∆PdeA cells) gene.
50ml cultures containing these cell lines were grown up under inducing conditions
overnight. The next day, cultures were back diluted to the sameOD600 and allowed to
grow another 90 minutes. The culture was then divided in half and cells were pelleted in
separate tubes. One pellet was resuspended in 10ml of inducing media, while the other
was resuspended in 10ml of media containing glucose to turn off protein induction.
500ul samples were taken from cultures at each timepoint then spun down at 4,000 x g.
Supernate was disregarded and pellet was immediately frozen in dry ice. These pellets
were later resuspended in 2X SDS, spun down at 15,000 x g and heated at 65oC before
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loading onto an SDS-PAGE gel. Protein was visualized using western blotting
techniques and the antibodies listed in 6.1.3.
6.5 EGFP degradation assay
This assay was done using an N-terminally EGFP labeled substrate. The
degradation reaction is carried out in a black 384 well plate treated with a non-stick
protein compound using a SpectraMax M5. Readings are taken with an excitation
wavelength between 444 and 460 and an emission wavelength between 540and 545.
Degradation assays final concentrations were as follows unless noted otherwise:
ClpX 0.2uM, ClpP 0.4uM, ATP 4mM, 75ug/ml Creatine Kinase, 5mM Creatine, GTP
1mM, substrate 2.5uM, CpdR 2.5uM (if present). Reaction components are mixed and
extra volume is filled with H-buffer. In the absence of CpdR, the volume of protein is
substituted with H-buffer. Reaction is begun by adding ATP, Creatine Kinase, and
Creatine Phosphate to a master mix containing ClpX, ClpP and GTP. All reactions are
carried out at 30 oC.
6.6Crystal Tray Setup
6.6.1 Sitting Drop
A single 96-well crystal screen was done using G130 diluted into water to
determine initial crystallization conditions. G130 was purified as in 6.2.1 and
subsequently concentrated down then diluted into MilliQ H2O filter sterilized in a 0.22
micron Millex sterile syringe filter. Concentration of G130 was done using a
5,000MWCO Vivaspin 500 tabletop centrifuge concentrator. A sample of volume of
G130 would be reduced approximately 10-fold and diluted back to original sample
volume with H2O up to at least 5 times to dilute out original buffer.
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G130 was then concentrated a final time to a concentration of no less than 6.26
mg/ml and 1 ul was put into each 2/3of a Corning 96 Well COC Protein Crystallization
Microplate with 3:1, 2µL Conical Flat Bottom Wells in each. Each reservoir was filled
with a corresponding number solution from the Qiagen JCSG+ Suite.
E.g.: Reservoir A1 corresponds to solution 1, Reservoir A2 corresponds to solution 2,
Reservoir B1 Corresponds to solution 13 etc.
1ul of the reservoir solution in each block was put into each of the 3 wells in a
block. Then, one well additionally had 1ul of the protein sample with highest
concentration from the concentrated stock. A second well additionally had 1ul of protein
that was mixed in a 1:1 ratio with H2O. The third well in each block additionally had a
control well for 1ul of protein at a lower concentration or buffer alone.
All reservoir solutions were pipette in row-by-row using a 10 barrel multi-channel
automated pipette with 50ul of solution in each reservoir. Then all columns but the
leftmost one was then covered with a piece of parafilm. The wells of one exposed row
were then filled with 1ul of the reservoir solution taken from the reservoir in the same
block using a manual pipette pressing the plunger down until the first stop (never fully
expelling liquid past the first stop). Subsequently, the appropriate protein samples were
pipetted into the wells manually in the same fashion.
The ideal crystallization condition in the screen was B7, 0.1M Sodium Acetate pH
4.6 and 8% (w/v) PEG 4,000 incubated at 20 oC. After a successful screen, hanging drop
plates were assembled to scale-up and optimize crystal growth.
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6.6.2 Hanging Drop
Hanging drop crystal plates were set up 4 x 6 pre-greased hanging drop plates.
Three drops were set up using a manual pipet on a glass cover slip. Drops were set-up as
described in 6.6.1 with the same ratio of protein solution to reservoir solution. The same
concentrations of G130 were used as in 6.6.1.
Reservoir solutions were set up individually based on the condition being tested.
Stock solutions of individual components were made and filtered with a 0.22um filter
before tray set up. Each component was manually pipetted into the reservoir individually
prior to drop setup. Optimal crystal conditions for G130 growth were 0.1M Sodium
Acetate pH 4.5 and 4% (w/v) PEG 4,000 incubated at 20 oC.
Phasing was done using a Mercury Acetate (Hampton Research) solution which
targets deprotonated cysteins and thus reacts better at higher pH values. Crystals were
therefore alternatively grown up in 0.1M HEPES pH 7.5 and 4% (w/v) PEG 4,000
incubated at 20 oC. After crystals were grown, 5 microliters of a solution containing
0.1M HEPES pH 7.5 and 4% (w/v) PEG 4,000 and 10mM Mercury Acetate was added to
the crystal drop directly. Crystals were allowed to incubate another 24 hours at 20 oC
before X-ray treatment.

6.7 Gel Filtration
Gel filtration experiments were done using a GE ATKA Purifier UPC 10 FPLC
with a GE Superdex 75 10/300 GL (Instruction #71-5017-96 AF). The column was
equilibrated with H-buffer prior to protein injection. 110ul of a pure protein sample at a
given concentration were loaded onto a 100ul loop and injected over the Superdex 75.
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Pump flow was 0.5ml/min with an initial pump of 1ml through the system itself before
column injection. Fractions were collected in 500ul samples for 24mls. Elution volumes
of a set of 6 standards were fit to alogarithmic curve and molecular weight of injected
samples were compared to this set to estimate molecular weight.

6.8 Heterodimerization Degradation Assay
6.8.1 In vitro Heterodimerization Degradation Assay
Same steps taken here as in 6.3 except protein sample was a protein sample at
equimolar concentrations of R69A and G130 incubated in an eppendorf tube at room
temperature overnight prior to set up of the assay.
6.8.2 In vivo Heterodimerization Degradation Assay
Same steps taken here as in 6.4 except WT CB15N cells with R69A expressed in
a 477 vector were subjected to the assay in tandem with ∆PdeA CB15N with R69A
expressed similarly.
6.9 Motility Assay
Cells expressing a given construct in the 477 vector(spectinomycin resistant,
medium copy, xylose promoter containing plasmids) were used in this assay. At least
one colony of cells was scooped manually onto the end of a pipet tip and stabbed straight,
half way to the bottom of a plate containing 0.3% PYE Agar with 50ug/ml
Spectinomycin. The agar either included no added sugars or 0.2% Xylose to induce
protein expression. Plates were then incubated at 30 oC for up to 4 days.
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Table 2: Table of Strains and Plasmids
Index Number

Cell Line

Vector

Antibiotic Selection Growth Medium

KRPC1

WTCB15N

477 PdeA

Spectinomycin

PYE

KRPC2

WTCB15N

477 ∆N

Spectinomycin

PYE

KRPC3

WTCB15N

477 ∆PAS

Spectinomycin

PYE

KRPC4

WTCB15N

477 PAS

Spectinomycin

PYE

KRPC5

WTCB15N

477 PdeA-DD

Spectinomycin

PYE

KRPC6

WTCB15N

477 R69A

Spectinomycin

PYE

KRPC7

∆PdeACB15N

477 PdeA

Spectinomycin

PYE

KRPC8

∆PdeACB15N

477 ∆N

Spectinomycin

PYE

KRPC9

∆PdeACB15N

477 ∆PAS

Spectinomycin

PYE

KRPC10

∆PdeACB15N

477 PAS

Spectinomycin

PYE

KRPC11

∆PdeACB15N

477 PdeA-DD

Spectinomycin

PYE

KRPC12

∆PdeACB15N

477 R69A

Spectinomycin

PYE

KRPC13

∆PdeACB15N

477 GFP-ssrA

Spectinomycin

PYE

KRPC14

E.coli Top10

pET23SUMO PdeA-DD

Ampicillin

LB

KRPC15

E.coli Top10

pET28 EGFP-E265-ssrA

Ampicillin

LB

KRPC16

E.coli Top10

pET28 EGFP-E265-AVAA

Ampicillin

LB

KRPC17

E.coli Top10

pET23SUMO E265

Ampicillin

LB

KRPC18

E.coli Top10

pET23SUMO S82-R280

Ampicillin

LB

KRPC19

E.coli Top10

pet23SUMO L131-E265

Ampicillin

LB

KRPC20

E.coli Top10

pet23SUMO PAS

Ampicillin

LB

KRPC21

E.coli Top10

pet23SUMO ∆N

Ampicillin

LB

KRPC22

E.coli Top10

pet23SUMO ∆N-G130

Ampicillin

LB

KRPC23

E.coli Top10

pet23SUMO R69A

Ampicillin

LB

KRPC24

E.coli Top10

pet23SUMO PdeA-ssrA

Ampicillin

LB

KRPC25

E.coli Top10

pet23SUMO E265-ssrA

Ampicillin

LB

KRPC26

E.coli Top10

pet23SUMO ∆PAS

Ampicillin

LB
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CHAPTER 7
RELEVANT TERMS
Term

Description

A protein domain with diguanylate cyclase activity characterized by an
active site containing the amino acid sequence GGDEF. GTP can bind
GGDEF on the GGDEF motif. The characteristic activity of this domain results in
Domain the cyclization of two molecules of GTP into one of cyclic-di-GMP.

GEDEF
Domain

A protein domain characterized by a GTP binding site containing the
amino acid sequence GEDEF. Binding of GTP to this domain can serve
to allosterically activate an alternative EAL domain. This domain is
unable to cyclize GTP into cyclic-di-GMP and is therefore referred to as
“degenerate”.

EAL
Domain

A protein domain with diguanylate phosphodiesterase activity
characterized by a conserved amino acid seqeuence motif EAL. Cyclicdi-GMP can bind to this domain. The characteristic activity of this
domain results in the linearization of one molecule of cyclic-di-GMP into
pGpG.

PAS
Domain

A protein domain that can function as a signal sensor and ligand binding
domain. The domain is named as "PAS" for three types of proteins the
domain occurs in: P: Per: Period Circadian Protein A: Arnt: Aryl
hydrocarbon receptor nuclear translocator protein, S: Sim: Single-minded
protein. These domains generally have low sequence homology, but high
structural homology.

Cyclicdi-GMP

A small molecule involved in bacterial signal transduction. Usually
synthesized by cyclization of two molecules of GTP. Upregulation or
downregulation of cyclic-di-GMP levels in a cell can lead to alternative
signalling events. Levels are upregulated by diguanylate cyclases and
downregulated by phosphodiesterases.
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